Benzinga | Dec 27, 2021 06:22AM EST

Ascendiant Capital Initiates Coverage On Lucid Diagnostics with Buy Rating, Announces Price Target of $16

Ascendiant Capital analyst Edward Woo initiates coverage on Lucid Diagnostics (NASDAQ:LUCD) with a Buy rating and announces Price Target of $16.